Kornimate/medical-research-clean huggingface dataset:
levels of high-sensitivity c-reactive protein in heart transplant patients

Conditions: Heart Transplant Failure; Periodontitis; Crp

Summary: objectives: the outcomes of heart transplantation are very favorable but inflammation still plays a critical role in deterioration of chronic transplants. periodontal diseases are not only limited to supporting structures of the teeth, they also cause systemic inflammation. based on the importance of inflammation in heart transplant recipients and the association between periodontal disease and systemic inflammation, this study explored whether periodontitis may be a modifier of serum high-sensitivity c-reactive protein (hscrp) in heart transplant patients.


Eligibility criteria:
inclusion criteria: be clinically stable be at least 1 year post-transplant; no history of antibiotic use during the preceding 4 months have had no periodontal treatment within the previous year. exclusion criteria: having other systemic infections

Keywords: heart transplant periodontitis hscrp
hemodynamic implications of transcatheter tricuspid valve repair in hfpef patients

Conditions: Congestive Heart Failure; Tricuspid Regurgitation

Summary: the aim of the study is to investigate the pathophysiological implications of transcatheter tricuspid valve edge-to-edge repair in patient with heart failure and preserved ejection fraction and severe tricuspid regurgitation. changes in right- and left-ventricular function as well as the interventricular dependence will be analysed on a multimodal basis including pressure-volume loop analysis and cardiac magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * severe tricuspid regurgitation with need for interventional treatment approach as decided by an interdisciplinary heart team. * signs and symptoms of left-sided heart failure. * left-ventricular ejection fraction ≥50% * invasive evidence of elevated left-ventricular fillings pressures (pulmonary capillary wedge pressure \[pcwp\] or left-ventricular end-diastolic pressure ≥15 mmhg) exclusion criteria: * concomitant relevant mitral valve regurgitation with need for concomitant interventional treatment * moderate aortic stenosis. * pregnancy * contraindication to perform cardiac magnetic resonance imaging. * conditions rendering patient unable to give informed consent to the study protocol.

Keywords: heart failure with preserved ejection fraction tricuspid regurgitation transcatheter tricuspid valve edge-to-edge repair
efficacy of huexc030 in subjects with pulmonary tuberculosis

Conditions: Pulmonary Tuberculosis

Summary: assess the efficacy of huexc030 as add-on excipient to eradicate anti-tuberculosis drugs induced hepatic injury ( atdh ) in subjects with pulmonary tuberculosis

the study drug is isoniazid formulated with huexc030 as excipient for eradicating atdh, whereas the reference control is isoniazid formulated with inactive excipient. subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study. eligible subjects will be randomized in a 1:1 ratio to receive study drug or reference control drug. subjects will be genotyped according to a selected panel of single nucleotide polymorphisms (snps) and categorized into high risk or low risk groups for occurring atdh via a specific haplotype consists of cyp2e1 and nat2 snps. based on an extensive study result during 2007 to 2011,the estimated frequency for patients bearing high risk genotypes in taiwanese population is around 25%. approximately 352 subjects will be enrolled for genotype screening in order to recruit 88 high risk subjects for each of 44 subjects in the intervention and control arms. subjects who are stratified as high risk groups will be administered the test drug or reference control drugs oral daily for 6 months or until treatment completion, i.e. bacteriologically confirmed negative of active m. tuberculosis. subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional tb medication under the care of their investigator for at least one follow-up visit at 4 weeks after the end of study.

Eligibility criteria:
main inclusion criteria: 1. a definite case of pulmonary tb 2. patient who is exposed to 3 or less doses of first-line anti-tb drug treatment for current disease. 3. age ≥ 20 years 4. have well documented baseline liver function tests that indicates patient's adequate liver function for enrollment to study. i. ast and alt \< 3x uln ii. total serum bilirubin \< 2.0 mg/dl main exclusion criteria: 1. have alcoholic liver disease or habitual alcohol consumption \> 30 g/day for more than one year 2. previously diagnosed of: i. extra-pulmonary tb without concomitant lung invasion ii. hiv iii. liver malignancy iv. liver cirrhosis v. any other systemic diseases that may cause liver dysfunction 3. documented history of serious allergic reaction or resistance to isoniazid, rifampicin, ethambutol, pyrazinamide, sugar alcohols or any structurally related compounds 4. subjects who will be using the following therapies after tb treatment starts: i. antiretroviral agents ii. oral corticosteroids 5. subjects are pregnant or lactating 6. subjects with child-bearing potential who are not committed to take reliable contraception during the participation of the study and at least 4 weeks after the end of the study treatment 7. subjects with any other serious disease considered by the investigator not in the condition to enter into the trial

Keywords: huexc030 pulmonary tuberculosis
effects of micro-osteoperforation on the maxillary first molar distalization

Conditions: Accretions; Teeth

Summary: the study aimed to evaluate the effect of different types of micro-osteoperforation on the rate of distal movement of maxillary first molars as a primary out come. besides, it was aimed to study secondary effect on the first molars by evaluating root resorption, bone density, and level of the pain during performing the procedures.

in the study, investigators tried to evaluate two methods to accelerate tooth movement by comparing them with control group. the first method was to apply one-time micro-osteoperforation. the second method was to apply the micro-osteoperforation repeatedly till reaching the end of the phase one treatment.

Eligibility criteria:
inclusion criteria: * space deficiency in the upper arch \> 5 mm, and \< 8 mm. * non-extraction lower arch. * full upper dentition up to the second molars. * third molar present in both sides, not yet erupted. exclusion criteria: * systemic disease or syndrome. * evidence of root resorption. * poor oral hygiene. * previous orthodontic treatment * evidence of bone loss. * active periodontal disease. * pregnant females. * presence of oral habits
randomized trial comparing titan stent with zotarolimus-eluting stent

Conditions: Coronary Heart Disease

Summary: a randomized comparison of a titanium-nitride-oxide coated stent (helistent titan2, hexacath) with a zotarolimus-eluting stent (endeavortm, medtronic) for percutaneous coronary intervention

objectives: the purpose of this study is to compare the titanium-nitride-oxide coated stent (helistent titan2, hexacath) with a zotarolimus-eluting stent (endeavortm, medtronic) in a non-inferiority trial. design: prospective, multi-center, randomized, non-inferiority trial to be conducted at 3 swiss interventional cardiology centers. patients will be randomized in a single-blind fashion (1:1 randomization) to either the titanium-nitride-oxide coated stent (helistent titan2, hexacath) or the zotarolimus-eluting stent (endeavortm, medtronic). study population: patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, unstable angina, and non-st elevation myocardial infarction, who qualify for percutaneous coronary interventions antiplatelet therapy: aspirin 100 mg qd indefinitely; clopidogrel 75 mg qd for 3 months enrollment: a total of 300 patients will be enrolled all patients will undergo repeat angiography at 6-8 months. all patients will be followed for up to 5 years.

Eligibility criteria:
inclusion criteria: the following patients are eligible for inclusion 1. age ≥18 years 2. symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, unstable angina, and non-st elevation myocardial infarction 3. presence of one or more coronary artery stenoses \>50% in a native coronary artery from 2.25 to 4.0 mm in diameter that can be covered with one or multiple stents; 4. no limitation on the number of treated lesions, and vessels, and lesion length exclusion criteria: 1. pregnancy 2. known intolerance to aspirin, clopidogrel, heparin, stainless steel, titan, zotarolimus or contrast material 3. inability to provide informed consent 4. currently participating in another trial before reaching first endpoint 5. st segment elevation myocardial infarction (stemi)

Keywords: coronary revascularization titanium-nitride-oxide coated stent zotarolimus-eluting stent
impact of ambulatory management for primary spontaneous pneumothorax in the emergency department on quality of life

Conditions: Primary Spontaneous Pneumothorax; Quality of Life; Ambulatory Care; Chest Tube

Summary: outpatient treatment of primary spontaneous pneumothorax (psp) compared to usual inpatient management could improve quality of care and represent a more efficient, generalizable and sustainable strategy. this multicenter, cluster-controlled, randomized interventional study with stepped wedge implementation will evaluate the impact on quality of life (between inclusion, after drain placement, and 6 months) of an ambulatory strategy for the management of large abundance primary spontaneous pneumothorax in the emergency department, compared with usual care.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 50 years presenting to the emergency department with a 1st episode of right or left primary spontaneous pneumothorax (psp) of large abundance diagnosed by chest x-ray or ct scan defined according to british thoracic society (bts) recommendations as a detachment greater than 2 cm over the entire height of the axillary line. * patient living less than an hour from hospital and able to be accompanied for the first 48 hours * patient able to understand the aims and risks of the research and to give informed, dated and signed consent * patient with internet access and able to complete online questionnaires * patient affiliated to or benefiting from a social health insurance exclusion criteria: * small pneumothorax (≤ 2cm) * suffocating pneumothorax defined by the presence of signs of respiratory distress or hemodynamic failure with indication for emergency exsufflation * patient on emergency oxygen or long-term oxygen therapy * traumatic pneumothorax * secondary spontaneous pneumothorax * bilateral pneumothorax * associated fluid effusion * risk-benefit balance unfavorable to outpatient treatment (comorbidities, isolated patient, difficulty understanding monitoring instructions) * patient living more than one hour from hospital * patients living alone or unable to be accompanied on discharge for the first 48 hours * patients under legal protection * pregnant or breast-feeding women * patient participating in a therapeutic interventional clinical trial or in a period of exclusion linked to previous participation in a clinical trial

Keywords: chest tube drainage primary spontaneous pneumothorax ambulatory management quality of life
rivaroxaban in type 2 myocardial infarctions

Conditions: Type II Myocardial Infarction

Summary: this trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.

this trial is an investigator-initiated prospective, single-center, placebo-controlled, double blinded, pilot randomized controlled trial of low-dose rivaroxaban (2.5mg oral twice daily) for 90-days following a type 2 myocardial infarction. the primary feasibility outcome is time to recruitment of 100 participants, stratified by sex.

Eligibility criteria:
inclusion criteria: 1. participant age ≥ 65years or \>45 years and an additional risk factor (smoking, diabetes mellitus, hypertension, dyslipidemia or known atherosclerotic disease) 2. rise in troponin level, with one troponin value above the 99th percentile of the upper limit of normal deemed to be due to a type 2 myocardial infarction by the attending team within the past 30 days 3. alive at the time of hospital discharge exclusion criteria: 1. current use of anticoagulation 2. current use of dual antiplatelet therapy 3. advanced kidney disease (egfr \<15ml/min) 4. previous hemorrhagic stroke at any time or embolic stroke within the past year 5. previous life-threatening bleeding event 6. life expectancy less than one year 7. anticoagulation recommended conditions - atrial fibrillation, pulmonary embolism, deep vein thrombosis, mechanical heart valves, rheumatic mitral valve disease, left ventricular thrombosis 8. surgery in the previous 30 days 9. inability to provide informed consent in english 10. pregnancy, breastfeeding or child bearing potential

Keywords: myocardial injury type ii myocardial infarction anticoagulation
prevalence of chronic obstructive pulmonary disease (copd) and eosinophilia among primary care patients

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: early diagnosis and appropriate treatment for copd subjects are both critical to minimize the progression of copd and improve outcomes. also, evidence suggests that high eosinophil (specific type of white blood cell that protects body against certain kinds of germs) level is associated with increased risk of both moderate and severe exacerbations in copd subjects. to date, there is insufficient amount of data that describes the prevalence of copd in brazilian primary care units. thus, this multicenter, cross-sectional study conducted in five centers located in five different brazilian cities will provide estimation about the prevalence of copd in primary care and will also determine the levels of eosinophils in subjects with confirmed copd diagnosis. approximately 2,500 eligible subjects are expected to be enrolled in the study.

the study is a cross sectional (prevalence study).

Eligibility criteria:
inclusion criteria: * adult \>= 35 years old * at least one of the following risk factors for copd: • being a current smoker (who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes) or past smoker (who has smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview); current or past exposure to biomass smoke, such as wood or coal, for cooking or heating (exposure \>=100 hours/year * capable of giving signed informed consent exclusion criteria: * physical or mental disability to complete the study procedures * heart above 120 beats per minute * participants under treatment for tuberculosis * participant in current clinical trial * pregnancy * patients with one of the following contraindications to spirometry: chest surgery in the last month; abdominal surgery within the past three months; neuromuscular disease, acute coronary syndrome; retinal detachment; hospitalization for any cardiac problem in the prior 3 months.

Keywords: eosinophilia copd prevalence primary care subjects
validation of a rapid quantitative test for loss of smell in covid-19 subjects

Conditions: COVID-19

Summary: the purpose of this study is to evaluate the performance of a non-invasive olfactory device as a rapid indicator of covid-19 in positive subjects.

the major hypothesis is that a quantitative and unbiased smell test will be a useful tool to identify covid-19 positive individuals. the study will address what fraction of outpatients truly have a loss-of-smell (including a partial loss) and is expected to outperform the current question that is used to identify covid-19 related anosmia "do you have a new loss of smell or taste?" (yes/no) in terms of sensitivity and specificity. the study will address if high-risk asymptomatic people whom are sars-cov-2 positive have a partial (or perhaps transitory) loss of smell. the primary objective of this study is to validate the utility (sensitivity, specificity and accuracy) of a quantitative non-biased olfactory device for the rapid identification of sars-cov-2 infected subjects (as identified by pcr). the performance of the device will also be compared to the standard cdc patient query for 'new loss of smell or taste'. the secondary objective is to test if sars-cov-2 positive 'asymptomatic' covid-19 subjects may actually present with a mild or transitory defect in smell (hyposmia), which is revealed through our quantitative olfactory smell test.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * have a corresponding pcr test for sars-cov-2 on the same day. exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * individuals with allergic to fragrances * history of surgery on the nose or paranasal sinuses * asthmatics * patients with known neurocognitive disorders: dementia, alzheimer's disease, parkinson's disease * adults with acute or chronic rhinosinusitis (they will be asked if they have a 'stuffy or runny nose'; they may be included in some tests, but their analysis would be segregated as they may be false positives due to allergies or a common cold or flu)

Keywords: olfactory device covid-19
study on symptom clusters during chemotherapy in ovarian cancer patients with different chinese medicine constitution

Conditions: Ovarian Cancer; Radiotherapy Side Effect; Symptom Cluster

Summary: the goal of this observational study is to learn about in patients treated with postoperative chemotherapy for ovarian tumors. the main questions it aims to answer are: • \[what symptom clusters are present in patients treated with postoperative chemotherapy for ovarian tumors\] • \[are there differences in symptom clusters for patients with different tcm body types\] participants will \[complete questionnaires prior to the start of chemotherapy and after the 1st, 3rd, and 6th chemotherapy treatments\].


Eligibility criteria:
inclusion criteria: pathologic diagnosis of ovarian cancer, the treatment plan adopts surgery combined with chemotherapy. age ≥ 18 years old, know the real situation of the disease, the expected survival period \> 1 year. general condition is good, no history of psychiatric disease, no serious heart, brain, liver, kidney function abnormality. informed consent and voluntarily participate in this study. exclusion criteria: those who have other tumors or whose diagnosis is unclear. those who cannot communicate properly, understand the questionnaire or complete the scale assessment. those who receive additional psychological interventions during the study period.
effect of liraglutide in obese women with polycystic ovary syndrome

Conditions: Polycystic Ovary

Summary: the aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with pcos.

it is a prospective randomized controlled trial .the study will include 80 randomly selected infertile women aged between 18 and 45 years, from gynecology and obstetrics department beni-suef university hospital whom diagnosed with polycystic ovarian syndrome (pcos), the study will include two groups; each group consists of 40 patients:- * group1 (n=40) will be treated by liraglutide monotherapy. * group 2 (n=40) will be treated by metformin monotherapy. * group 3 (n=40) will be a control group. to assess the metabolic effect of each treatment, the following parameters will be assessed before and after the treatment * to assess the hormonal effect of each treatment, the following tests will be assessed before and after treatment * total testosterone (tt) * dehydroepiandrosterone (dhea) to assess the clinical effect of the drugs, the following will be assessed before and after treatment: the number of medium size follicles and large size follicles and the endometrium thickness were assessed on the tenth or eleventh day of menstruation. the chemical and clinical pregnancy rates were evaluated

Eligibility criteria:
inclusion criteria: * aged between 20 and 45 years * pco exclusion criteria: 1. congenital adrenal hyperplasia 2. poorly controlled thyroid disease 3. taking antidiabetic drugs which can affect insulin resistance 4. chronic kidney disease and history of recurrent urinary tract infections 5. liver dysfunction 6. documented use of oral hormonal contraceptives and hormone-releasing implants

Keywords: polycystic ovary liraglutide
effectiveness of nutritional interventions for cancer patients undergoing chemotherapy

Conditions: Gastric Cancer; Colon Cancer

Summary: this study aims to estimate the effects of nutritional interventions on the improvement of nutritional status and quality of life (qol) among gastrointestinal patients in vietnam

a quasi-experiment with intervention and control groups for pre- and post-intervention assessment was carried out at the department of oncology and palliative care - medical university hospital from 2016 to 2019. 60 gastrointestinal cancer patients were recruited in each group. at stage 1, we selected patients of the intervention group who met the inclusion criteria to receive nutritional counseling and diet at the hospital. at stage 2, we chose patients who were eligible but did not accept the nutritional counseling and diet at the hospital. participants in both groups were paired together according to the following criteria: 1) age group: \ 65 years old; 2) gender: male and female; 3) types of cancer: stomach cancer and colon cancer; 4) disease stages: stage 1-2 and stage 3-4.

Eligibility criteria:
inclusion criteria: * aged 18 years old or above * diagnosed with stomach or colon cancer; * at the initial of receiving chemotherapy treatment; * indicated for oral feeding; * not having co-morbidities of chronic diseases such as kidney failure, heart failure, liver failure, diabetes; * having ability to communicate with data collectors and both attending doctors and agreeing to involve in the study exclusion criteria: * treated by other methods such as radiation, endocrine, immunity; * undergoing terminal palliative care; * having contraindications to oral feeding/enteral nutrition